Nutriop

AgeX-Ohio State collaborate on diabetes therapy

Latest articles

Dyno Therapeutics closes $100m to accelerate gene therapy

Dyno Therapeutics closes $100 million Series A led by Andreessen Horowitz to accelerate AI-powered gene therapy platform. Dyno Therapeutics, Inc, a biotech applying AI to...

Sticking with glutathione could be a smart longevity choice

The body's "master antioxidant" glutathione is a powerful weapon in the fight for longevity, but it diminishes with age; AgelessRx has a range of...

Rise of the retrons – a new gene editing technique

Move over CRISPR... a new gene editing technique enables millions of genetic experiments to be performed simultaneously. Like the best B Movie ever, The Day...

VitaDAO announces “Longevity Molecule” research project

VitaDAO will use advanced machine learning to crunch the data from 1.04 billion prescriptions to understand the impact of drugs on human lifespan. VitaDAO, which...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

Dyno Therapeutics closes $100m to accelerate gene therapy

Dyno Therapeutics closes $100 million Series A led by Andreessen Horowitz to accelerate AI-powered gene therapy platform. Dyno Therapeutics, Inc, a biotech applying AI to...

Sticking with glutathione could be a smart longevity choice

The body's "master antioxidant" glutathione is a powerful weapon in the fight for longevity, but it diminishes with age; AgelessRx has a range of...

Rise of the retrons – a new gene editing technique

Move over CRISPR... a new gene editing technique enables millions of genetic experiments to be performed simultaneously. Like the best B Movie ever, The Day...
Nutriop

AgeX Therapeutics set to collaborate with The Ohio State University to generate proof-of-concept animal data for AgeX’s brown adipose tissue (BAT) cell therapy candidate for diabetes and obesity.

AgeX Therapeutics, a biotech developing therapeutics for human aging and regeneration, announced today a research collaboration with The Ohio State University using AgeX’s brown adipocyte tissue (BAT) cell therapy candidate AgeX-BAT1 in mice to determine whether transplantation of AgeX-BAT1 cells may improve diet-induced obesity, metabolic health including glucose metabolism and cardiac function.

Longevity.Technology: Diabetes and obesity are significant threats to both lifespan and healthspan, and their prevalence has been increasing year on year. AgeX specifically targets metabesity – the constellation of interconnected diseases with metabolic roots – with AGEX-BAT1, lining up type 2 diabetes and age-related metabolic disorders in its sights.

The research will be conducted in the laboratory of world-leading BAT researcher Kristin Stanford, PhD, Associate Professor in Physiology & Cell Biology and Associate Director of the Diabetes and Metabolism Research Center at The Ohio State University Wexner Medical Center.

Kristen Stanford, PhD, associate professor at OSU
Kristen Stanford, PhD, Associate Professor at OSU

As an early pioneer in BAT transplantation, Dr Stanford transplanted BAT from donor mice into recipient mice. By 8–12 weeks post transplantation, recipient mice had improved glucose tolerance, increased insulin sensitivity, lower body weight, reduced fat mass, and a full reversal of high-fat diet-induced insulin resistance [1]. This year, Dr Stanford became the first person to show a direct role for BAT to enhance cardiac function [2].

“We will be investigating the potential of human pluripotent stem cell-derived brown adipose tissue (BAT) to improve metabolic health and cardiac function.” said Dr Stanford. “The preclinical research studies may provide the basis for future therapeutic interventions in diabetes and obesity as well as provide new insights into the role of BAT.”

AgeX’s BAT cells may have advantages over other sources of BAT given published data show that AgeX’s pioneering PureStem® cell derivation and manufacturing technology platform is able to generate highly pure and scalable BAT cells, potentially providing an unlimited source of cells [3]. AgeX-BAT1 consists of BAT progenitor cells that are capable of becoming BAT.

 


 

“The preclinical research studies may provide the basis for future therapeutic interventions in diabetes and obesity as well as provide new insights into the role of BAT.”

 


 

“We are delighted to collaborate with Dr Kristin Stanford, who has dedicated her career to understanding brown adipose tissue (BAT). The research could generate proof-of-concept data in an animal model for AgeX’s BAT cell therapy candidate AgeX-BAT1,” said Dr Nafees Malik, Chief Operating Officer of AgeX. “AgeX’s BAT cells may offer an innovative therapeutic strategy for diabetes and obesity, which present potential multi-billion-dollar market opportunities, given 13% of adults in the US suffer from diabetes and 42% from obesity.”

Find out more about AgeX’s potential merger with LyGenesis HERE.

[1] https://pubmed.ncbi.nlm.nih.gov/23221344/
[2] https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.049813
[3] https://stemcellres.biomedcentral.com/articles/10.1186/s13287-018-1087-7

Images courtesy of AgeX and OSE

Comment on this article

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
Nutriop

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...
Supplement report

Related articles

Dyno Therapeutics closes $100m to accelerate gene therapy

Dyno Therapeutics closes $100 million Series A led by Andreessen Horowitz to accelerate AI-powered gene therapy platform. Dyno Therapeutics, Inc, a biotech applying AI to...

Rise of the retrons – a new gene editing technique

Move over CRISPR... a new gene editing technique enables millions of genetic experiments to be performed simultaneously. Like the best B Movie ever, The Day...

Metabolomics and biomarkers of healthy aging

Clinical studies planned to determine if metabolic biomarkers predictive of mortality can be used to identify people at risk for developing disease. Germany’s Max Planck...

Researchers find mechanism that clears senescent cells

UCSF discovery spotlights potential immune therapy for chronic disease and fibrosis. Scientists at UC San Francisco are leveraging the power of immune cells to clear...

Can CRISPR be used to diagnose aging?

Irina Conboy talks CRISPR and how the gene-editing tech may have a significant role to play in diagnostics. In the first article from our interview...
Nutriop